Latest Press releases
HepaRegeniX GmbH secures Series B Financing in excess of € 11 Mio. to advance first drug candidate to the clinic
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
HepaRegeniX GmbH announces management changes: Dr. Michael Lutz appointed as new CEO/Managing Director
Dr. Lutz is an experienced biotech entrepreneur who has spent the last 15 years at executive management positions with several Life Sciences companies...
HepaRegeniX GmbH Raises € 9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases
HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases, discovered by Prof. Lars Zender and his research group...